Compare RNST & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNST | VERA |
|---|---|---|
| Founded | 1904 | 2016 |
| Country | United States | United States |
| Employees | N/A | 249 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.9B |
| IPO Year | 1994 | 2021 |
| Metric | RNST | VERA |
|---|---|---|
| Price | $35.90 | $39.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $42.25 | ★ $81.30 |
| AVG Volume (30 Days) | 706.2K | ★ 988.9K |
| Earning Date | 04-21-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.64% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.83 | N/A |
| Revenue Next Year | $4.58 | $445.28 |
| P/E Ratio | $16.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.26 | $18.53 |
| 52 Week High | $42.11 | $56.05 |
| Indicator | RNST | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 42.64 | 43.90 |
| Support Level | $35.26 | $37.20 |
| Resistance Level | $37.99 | $43.21 |
| Average True Range (ATR) | 0.92 | 2.48 |
| MACD | -0.11 | 0.16 |
| Stochastic Oscillator | 44.71 | 37.19 |
Renasant Corp operates as a holding company for Renasant Bank, a Mississippi banking corporation, and its subsidiary, Renasant Insurance, Inc. It has three reportable segments: Community banks, Insurance, and Wealth management. With its Community banks segment, the company provides a range of financial services to individuals and small businesses. Its Insurance segment is an insurance agency providing commercial and personal insurance through third-party carriers. The Wealth management segment provides a range of services, including money management and retirement planning. The majority of the company's revenue is driven by lending activities in its community banks segment.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.